A randomized controlled pilot study of Pentoxifylline in patients with non-alcoholic steatohepatitis (NASH)
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Patients with biopsy proven NASH and persistently elevated alanine aminotransferase (ALT) greater than 1.5 times the upper limit of normal were randomized to 3 months of treatment with a step 1 American Heart Association diet and daily exercise with Pentoxifylline or placebo. Liver function tests, serum lipids and TNF-α, Interleukin 6 (IL-6), and plasma hyaluronic acid were measured at baseline, at weeks 6 and 12. Categorical data were analyzed by Fisher’s exact test while independent sample t-test and Mann–Whitney test were used for continuous data.
Eleven patients were randomized into the Pentoxifylline and nine to the placebo group. After 3 months of treatment body mass index (BMI), ALT and aspartate aminotransferase (AST) decreased significantly in both groups. There was no difference between the two groups in reduction of BMI (P = 0.897). There was significantly greater reduction in AST in the Pentoxifylline group (P = 0.038). There was a trend toward lower ALT level (P = 0.065) in the Pentoxifylline group. TNF-α and IL-6 decreased significantly in both groups after treatment, but there was no significant difference between the two groups.
- Younossi ZM, Diehl AM, Ong JP. Nonalcoholic fatty liver disease: an agenda for clinical research. Hepatology. 2002;35:743–52. CrossRef
- Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, et al. NASH and insulin resistance: insulin hypersecretion and specific association with insulin resistance syndrome. Hepatology. 2002;35:373–9. CrossRef
- Hill D, Shedolfsy F, McClain CJ, Diehl DM, Tsukamoto H. Cytokines and liver disease. In: Remick D, Freidland J, editors. Cytokines in health and disease. 2nd ed. New York: Marcel Dekker, 1997. p. 401–25.
- McClain CJ, Barve S, Deaciuc I, Kugelmas M, Hill D. Cytokines in alcoholic liver disease. Semin Liver Dis. 1999;19:205–19. CrossRef
- Tigl H, Diehl AM. Cytokines in alcoholic and non alcoholic steatohepatitis. N Engl J Med. 2000;343:467–76.
- Wigg AJ, Roberts-Thomson IC, Yock RB, McCarthy PJ. Crose RH, Cummins AG. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxemia and tumor necrosis factor—α in the pathogenesis of non alcoholic steatohepatitis. Gut. 2001;48:148–9. CrossRef
- Crespo J, Cayon A, Fernandez-Gil P, Hernandez-Guerra M, Mayorga M, Dominguez-Diez A, et al. Gene expression of tumor necrosis factor alpha and TNF-receptors p55 and p75, in non alcoholic steatohepatitis patients. Hepatology. 2001;34:1158–63. CrossRef
- Huakeland JW, Damas JK, Konopski Z, Loberg EM, Haaland T, Goverud I, et al. Systemic inflammation in non alcoholic fatty liver disease is characterized by elevated levels of CCL2. J Hepatol. 2006;44:1167–74. CrossRef
- Kugelmas M, Hill D, Marsano L, McClain CJ. Cytokines NASH: a pilot study of the effects of Lifestyle modification and Vitamin E. Hepatology. 2003;38:413–9. CrossRef
- Suzuki A, Angulo P, Lymp J, Li D, Saromura S, Lindor K. Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in paitents with non alcoholic fatty liver disease. Liver Int. 2005;25:779–86. CrossRef
- Strieter R, et al. Cellular and molecular regulation of tumor necrosis factor-alpha by pentoxifylline. Biochem Biophys Res Commun. 1988;155:1230–6. CrossRef
- Morgan TR. Pentoxifylline and alcoholic hepatitis. Gastroenterology. 2000;119:1787–91. CrossRef
- Akriviadis E, Botla R, Briggs W, Han S, Reynolls T, Shakil O. Pentoxifylline improves short term survival in severe acute alcoholic hepatitis: a double-blind, placebo controlled trial. Gastroenterology. 2000;119:1637–49. CrossRef
- Adams LA, Zein CO, Angulo P, Lindor KD. A pilot trial of pentoxifylline in non alcoholic steatohepatitis. Am J Gastroenterol. 2004;99:2365–8. CrossRef
- Satapathy SK, Garq S, Chauhan R, Sakhuja P, Malhotra V, Sharma BC, Sarin SK. Beneficial effects of tumor necrosis factor-alpha inhibition by pentoxifylline on clinical, biochemical, and metabolic parameters of patients with non alcoholic steatohepatitis. Am J Gastroenterol. 2004;99:1946–52. CrossRef
- Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;16:1413. CrossRef
- Brunt E, Janney CG, Di Bicegelie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging of the histological lesions. Am J Gastroenterol. 1999;94:2467–74.
- Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, et al. A placebo-controlled trial of Pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006;355:2297–307. CrossRef
- Zelber-Sagi S, Kessler A, Brazowsky E, Webb M, Lurie Y, Santo M, et al. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2006;4(5):639–44. CrossRef
- Satapathy SK, Garq S, Sakhuja P, Sakhuja P, Malhotra V, Sharma BC, et al. Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol. 2007;22:634–8.
- A randomized controlled pilot study of Pentoxifylline in patients with non-alcoholic steatohepatitis (NASH)
Volume 2, Issue 2 , pp 196-201
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Non-alcoholic steatohepatitis
- TNF alpha
- Randomized controlled study
- Industry Sectors
- Author Affiliations
- 1. Department of Gastroenterology/Hepatology, National University Hospital, 5 Lower Kent Ridge Road, Singapore, 119074, Singapore
- 3. Asia Center for Liver Disease and Transplantation, Gleneagles Hospital, 6A Napier Road, Singapore, 258500, Singapore
- 2. Department of Pathology, National University Hospital, 5 Lower Kent Ridge Road, Singapore, 119074, Singapore